Positron emission tomography evaluation of dopaminergic pathways

J. S. Perlmutter, C. A. Tamminga

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Positron emission tomography (PET) studies of dopamine receptors have provided exciting new insights into basal ganglia function that are particularly relevant to Parkinson's disease. Previous studies have concentrated on alterations in radioligand binding of primarily D2-like dopaminergic binding sites. Development of new radioligands with greater dopamine subtype specificity promises to reveal additional information about dopaminergic function. Also, pharmacological activation techniques with PET may permit identification of alterations in receptor-mediated pathways not associated with direct changes in receptors.

Original languageEnglish (US)
JournalClinical Neuropharmacology
Volume18
Issue numberSUPPL. 1
StatePublished - 1995

Fingerprint

Positron-Emission Tomography
Dopamine Receptors
Basal Ganglia
Parkinson Disease
Dopamine
Binding Sites
Pharmacology

Keywords

  • Dopamine
  • Parkinson's disease
  • Positron emission tomography
  • Receptors
  • Transmitters

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Positron emission tomography evaluation of dopaminergic pathways. / Perlmutter, J. S.; Tamminga, C. A.

In: Clinical Neuropharmacology, Vol. 18, No. SUPPL. 1, 1995.

Research output: Contribution to journalArticle

@article{b70174bab6d74ba38322acd1053677e0,
title = "Positron emission tomography evaluation of dopaminergic pathways",
abstract = "Positron emission tomography (PET) studies of dopamine receptors have provided exciting new insights into basal ganglia function that are particularly relevant to Parkinson's disease. Previous studies have concentrated on alterations in radioligand binding of primarily D2-like dopaminergic binding sites. Development of new radioligands with greater dopamine subtype specificity promises to reveal additional information about dopaminergic function. Also, pharmacological activation techniques with PET may permit identification of alterations in receptor-mediated pathways not associated with direct changes in receptors.",
keywords = "Dopamine, Parkinson's disease, Positron emission tomography, Receptors, Transmitters",
author = "Perlmutter, {J. S.} and Tamminga, {C. A.}",
year = "1995",
language = "English (US)",
volume = "18",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Positron emission tomography evaluation of dopaminergic pathways

AU - Perlmutter, J. S.

AU - Tamminga, C. A.

PY - 1995

Y1 - 1995

N2 - Positron emission tomography (PET) studies of dopamine receptors have provided exciting new insights into basal ganglia function that are particularly relevant to Parkinson's disease. Previous studies have concentrated on alterations in radioligand binding of primarily D2-like dopaminergic binding sites. Development of new radioligands with greater dopamine subtype specificity promises to reveal additional information about dopaminergic function. Also, pharmacological activation techniques with PET may permit identification of alterations in receptor-mediated pathways not associated with direct changes in receptors.

AB - Positron emission tomography (PET) studies of dopamine receptors have provided exciting new insights into basal ganglia function that are particularly relevant to Parkinson's disease. Previous studies have concentrated on alterations in radioligand binding of primarily D2-like dopaminergic binding sites. Development of new radioligands with greater dopamine subtype specificity promises to reveal additional information about dopaminergic function. Also, pharmacological activation techniques with PET may permit identification of alterations in receptor-mediated pathways not associated with direct changes in receptors.

KW - Dopamine

KW - Parkinson's disease

KW - Positron emission tomography

KW - Receptors

KW - Transmitters

UR - http://www.scopus.com/inward/record.url?scp=0029058150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029058150&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029058150

VL - 18

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - SUPPL. 1

ER -